IDgenetix® Shown to Significantly Improve Medication Response and Remission Rates in Patients with Major Depressive Disorder
May 31 2023 - 7:00AM
Business Wire
In the study, patients whose medication
management was guided by IDgenetix achieved a 35% increase in
medication response and a 64% increase in remission compared to
patients whose medication was not guided by the test
Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving
health through innovative tests that guide patient care, today
announced real-world study data demonstrating that use of
IDgenetix® to guide medication management can significantly improve
medication response and remission rates in patients diagnosed with
moderate to severe depression, compared to current standard-of-care
treatment. The data was shared via a poster presentation at the May
2023 American Psychiatric Association (APA) Annual Meeting held in
San Francisco.
“Unlike other pharmacogenomic tests, which only consider a
patient’s drug-gene interactions, IDgenetix takes into account a
patient’s drug-drug interactions and lifestyle factors, and can
provide a more comprehensive overview of which medications will be
effective therapies for the patient,” said Kelly Wosnik, DNP, NP-C,
owner and nurse practitioner at Bristol Health, and co-author of
the study. “As supported by the data in this study, using IDgenetix
to guide personalized medication selection can help improve the
care of patients suffering from moderate to severe depression by
offering hope of improved medication response and remission.”
In the study, patients whose medication management was guided by
IDgenetix achieved a 35% increase in medication response and a 64%
increase in remission rate at eight weeks compared to patients
whose medication was not guided by the test. These results
demonstrate the potential value of IDgenetix in guiding improved
medication management compared to the standard-of-care,
trial-and-error approach, and are consistent with the previously
published randomized control trial (RCT) using IDgenetix.1
The study abstract can be accessed via APA’s website here.
IDgenetix is Castle’s next-generation pharmacogenomic (PGx) test
that incorporates the results of a 15-gene variant panel with
drug-drug interaction data and lifestyle factors to provide
medication recommendations for patients with mental health
conditions, such as depression and anxiety. Using the IDgenetix
test report, clinicians may be able to more precisely tailor
treatments to individual patients, rather than relying on trial and
error, potentially reducing the chances of side effects or
ineffective treatments. In an RCT, patients diagnosed with severe
depression whose medication management was guided by the IDgenetix
test showed a greater than two and a half times improvement in
remission rates at eight and 12 weeks compared to those who were
not guided by IDgenetix.1
About IDgenetix® IDgenetix® is a pharmacogenomic (PGx)
product test for depression, anxiety and other mental health
conditions designed to analyze a patient’s genetic make-up to guide
timely and evidence-based decisions on the optimal drug for each
patient. IDgenetix is designed to provide important genetic
information to clinicians to help guide personalized treatment
plans for their patients, with the potential to help patients
achieve a faster therapeutic response and improve their chances of
remission by identifying appropriate medications more efficiently
than the standard-of-care, trial-and-error approach. IDgenetix
provides drug-drug and drug-gene interactions and is supported by a
published, peer-reviewed randomized controlled trial that
demonstrated clinical utility over the standard of care when
physicians used IDgenetix prior to prescribing a medication. More
information about Castle’s tests can be found at
www.CastleTestInfo.com.
About Castle Biosciences Castle Biosciences (Nasdaq:
CSTL) is a leading diagnostics company improving health through
innovative tests that guide patient care. The Company aims to
transform disease management by keeping people first: patients,
clinicians, employees and investors.
Castle’s current portfolio consists of tests for skin cancers,
uveal melanoma, Barrett’s esophagus and mental health conditions.
Additionally, the Company has active research and development
programs for tests in other diseases with high clinical need,
including its test in development to predict systemic therapy
response in patients with moderate-to-severe psoriasis, atopic
dermatitis and related conditions. To learn more, please visit
www.CastleBiosciences.com and connect with us on LinkedIn,
Facebook, Twitter and Instagram.
DecisionDx-Melanoma, DecisionDx-CMSeq, DecisionDx-SCC, MyPath
Melanoma, DecisionDx-UM, DecisionDx-PRAME, DecisionDx-UMSeq,
TissueCypher and IDgenetix are trademarks of Castle Biosciences,
Inc.
Forward-Looking Statements This press release contains
forward-looking statements within the meaning of Section 27A of the
Securities Act of 1933, as amended, and Section 21E of the
Securities Exchange Act of 1934, as amended, which are subject to
the “safe harbor” created by those sections. These forward-looking
statements include, but are not limited to, statements concerning:
the potential of IDgenetix to (i) significantly improve medication
response and remission rates in patients diagnosed with moderate to
severe depression compared to current standard of care treatment;
(ii) provide a more comprehensive overview of which medications
will be effective therapies for the patient; (iii) help improve the
care of patients suffering from moderate to severe depression by
offering hope of improved medication response and remission rate;
(iv) add value by guiding improved medication management compared
to the standard-of-care, trial-and-error approach; and (v) enable
clinicians to more precisely tailor treatments to individual
patients, rather than relying on trial and error, potentially
reducing the chances of side effects or ineffective treatments. The
words “can,” “may,” “potential,” “will” and similar expressions are
intended to identify forward-looking statements, although not all
forward-looking statements contain these identifying words. We may
not actually achieve the plans, intentions or expectations
disclosed in our forward-looking statements, and you should not
place undue reliance on our forward-looking statements. Actual
results or events could differ materially from the plans,
intentions and expectations disclosed in the forward-looking
statements that we make. These forward-looking statements involve
risks and uncertainties that could cause our actual results to
differ materially from those in the forward-looking statements,
including, without limitation: subsequent study or trial results
and findings may contradict earlier study or trial results and
findings or may not support the results shown in this study,
including with respect to the discussion of IDgenetix in this press
release; actual application of our tests may not provide the
aforementioned benefits to patients; and the risks set forth under
the heading “Risk Factors” in our Quarterly Report on Form 10-Q for
the quarter ended March 31, 2023, and in our other filings with the
SEC. The forward-looking statements are applicable only as of the
date on which they are made, and we do not assume any obligation to
update any forward-looking statements, except as may be required by
law.
1. Bradley P, Shiekh M, Mehra V, et al. Improved efficacy with
targeted pharmacogenetic-guided treatment of patients with
depression and anxiety: A randomized clinical trial demonstrating
clinical utility. J Psychiatr Res. 2018 Jan;96:100-107. doi:
10.1016/j.jpsychires.2017.09.024. Epub 2017 Sep 23. PMID:
28992526.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230531005163/en/
Investor Contact: Camilla Zuckero
czuckero@castlebiosciences.com
Media Contact: Allison Marshall
amarshall@castlebiosciences.com
Castle Biosciences (NASDAQ:CSTL)
Historical Stock Chart
From Jun 2024 to Jul 2024
Castle Biosciences (NASDAQ:CSTL)
Historical Stock Chart
From Jul 2023 to Jul 2024